Results 91 to 100 of about 1,181,836 (211)

Junior doctors' experiences with vulnerability: A rich picture study

Medical Education, EarlyView.
Abstract Context The transition to practice is a context in which junior doctors can feel vulnerable. Although we know junior doctors experience intense emotions during their transition to practice, we still do not understand the role of vulnerability in this process. Vulnerability may cause emotional suffering but also offers an opportunity for growth
Titia S. van Duin, Anne de la Croix, A. Debbie C. Jaarsma, Marco A. C. Versluis, Marco A. de Carvalho Filho   +4 more
wiley   +1 more source

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update [PDF]

, 2017
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management recommendations. A large international Task Force based decisions on evidence from 3 systematic literature reviews, developing
Aletaha, Aletaha, Aletaha, Aletaha, Aletaha, Aletaha, Aletaha, Aletaha, Andrea Rubbert-Roth, Atsumi, Axel Finckh, Baillet, Bejarano, Bernard Combe, Bijlsma, Breedveld, Brenol, Brouwers, Bruynesteyn, Buch, Burmester, Burmester, Burmester, Buttgereit, Bykerk, Cader, Cardiel, Cem Gabay, Chatzidionysiou, Choe, Choi, Choy, Chris D Buckley, Christophe Richez, Cohen, Coleman, Combe, Curtis, Cutolo, Dale, Daniel Aletaha, de Jong, De Stefano, del Rincón, Detert, Dixon, Dmitry Karateev, Dougados, Dougados, Duru, Désirée van der Heijde, Dörner, Eduardo Mysler, Emery, Emery, Emery, Emery, Emery, Emery, Emery, Emery, Feldman, Felson, Fleischmann, Fleischmann, Fleischmann, Frank Buttgereit, Fransen, Furst, Gabay, Gaujoux-Viala, Gaujoux-Viala, Gaujoux-Viala, Genovese, Genovese, Gerd Burmester, Goekoop-Ruiterman, Goekoop-Ruiterman, Guyatt, Gyula Poór, Götestam Skorpen, Haavardsholm, Hage, Hauser, Hazlewood, Hoes, Holloway, Huizinga, Iain McInnes, Jackie Nam, Jacques-Eric Gottenberg, Johanna M W Hazes, Johannes Bijlsma, Jones, Jose da Silva, Josef S Smolen, Juan Gomez-Reino, Kaneko, Karel Pavelka, Katchamart, Katerina Chatzidionysiou, Katz, Kavanaugh, Kenneth Saag, Kiely, Klarenbeek, Klareskog, Kyburz, Lahiri, Landewé, Lau, Laure Gossec, Lee, Lehman, Li, Linde, Listing, Maarten Boers, Maarten de Wit, Machold, Maini, Manders, Marieke Voshaar, Mario Cardiel, Marios Kouloumas, Martin Aringer, Maurizio Cutolo, Maxime Dougados, McCarty, Meghna Jani, Memel, Moreland, Mottonen, Moura, Nam, Nam, Nam, Nasonov, Navarro-Compán, Nell, O'Dell, O'Dell, OCEBM Levels of Evidence Working Group, Paul Emery, Pereira, Peter Nash, Peters, Piet van Riel, Porter, Prevoo, Provan, Radner, Radner, Ramiro, Ramiro, Ranganath, Rau, René Westhovens, Robert Landewé, Robinson, Ronald van Vollenhoven, Sakellariou, Schett, Schipper, Schoels, Schoels, Schumacher, Scott, Sharma, Singh, Singh, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Smolen, Sofia Ramiro, St Clair, Stoffer, Strangfeld, Strangfeld, Strehl, Tanaka, Tanja Stamm, Taylor, Thiele, Tom Huizinga, Tore Kvien, Torrente-Segarra, Tsutomu Takeuchi, van Aken, van Assen, van der Goes, van der Heide, van der Heijde, van der Heijde, van der Heijde, Van der Heijde, van der Heijde, Van der Heijde, van der Horst-Bruinsma, van Leeuwen, van Sijl, van Vollenhoven, Vastesaeger, Verschueren, Verschueren, Verstappen, Visser, Visser, Vivian Bykerk, Wasko, Weinblatt, Weinblatt, Widdifield, Wilske, Wollenhaupt, Xavier Mariette, Yoo, Yvonne van Eijk-Hustings, Zhanguo Li, Zink   +232 more
core   +13 more sources

Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients naïve to or switched from biologics.

Modern Rheumatology, 2021
OBJECTIVES The aim of this post-marketing surveillance (PMS) study is to evaluate the real-world safety and efficacy of CT-P13, the first biosimilar of infliximab (IFX).
T. Takeuchi, K. Nishikawa, Fumika Yamada, S. Ohshima, M. Inoue, Y. Yoshioka, H. Yamanaka   +6 more
semanticscholar   +1 more source

‘There's No Improvement. I'm Still Bedridden’: Recovery After Hospital Admission for Low Back Pain and Alignment With Patient Expectations

Musculoskeletal Care, Volume 24, Issue 2, June 2026.
ABSTRACT Background Patients with non‐serious low back pain (LBP) may present to hospital emergency departments expecting high‐value care when community healthcare options are perceived as inaccessible or ineffective. Objectives This study explored the experiences and expectations of patients following a LBP‐related admission to provide insight into ...
Joseph F. Orlando, Matthew Beard, Anne L. J. Burke, Michelle Guerin, Saravana Kumar   +4 more
wiley   +1 more source

INTRAABDOMINAL DESMOPLASTIC SMALL ROUND CELL TUMOR: CASE REPORT WITH LITERATURE REVIEW [PDF]

Euromediterranean Biomedical Journal, 2015
Intra-abdominal desmoplastic small round cell tumors are rare aggressive neoplasms, with a very poor prognosis, observed in young adults with a male predominance.
Joseph Kreiker
doaj   +1 more source

本邦におけるバイオ後続品の開発推進に関する研究 [PDF]

, 2018
武蔵野大学2017年
中川 直子
core   +2 more sources

Aggressive Desmoplastic Small Round Cell Tumor in an Adult: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive sarcoma that predominantly affects adolescents and young adults. It is defined by a characteristic chromosomal translocation, t(11;22) (p13;q12), resulting in the EWS–WT1 fusion gene.
Seyed Amir Aledavood, Ehsan Soltani, Mahsa Akbari Oryani, Hourieh Soleimani, Noushin Saleki   +4 more
wiley   +1 more source

Introduction of subcutaneous infliximab CT-P13 and vedolizumab in clinical practice: a multi-stakeholder position statement highlighting the need for post-marketing studies.

Journal of Crohn's & Colitis, 2022
BACKGROUND AND AIMS Although subcutaneous formulations of infliximab CT-P13 and vedolizumab are registered for treating moderate-to-severe inflammatory bowel disease (IBD), many questions on their use remain unanswered.
L. Fierens, C. Liefferinckx, E. Hoefkens, T. Lobatón, E. Dreesen, J. Sabino, M. Ferrante   +6 more
semanticscholar   +1 more source

The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed, Tasfiah Tasnim Maha, Sanjana Nowsher, Wasima Taslim, Fatema‐Tuz‐Zohora, Sabrina Sharmin, Hasina Yasmin   +6 more
wiley   +1 more source

Krónikus betegségek biológiai terápiájának alkalmazásával kapcsolatos gazdasági megfontolások = Economic consideration of the implementation of biotechnological therapies in chronic diseases [PDF]

, 2014
Disszertációmban egyes krónikus betegségekben alkalmazott biológiai terápiák gazdasági, pénzügyi és költségvetési hatásaival foglalkoztam. Célkitűzés: A biológiai gyógyszerek terápiás alkalmazásáról rendelkezésre álló tudás mind Magyarországon, mind a ...
Balogh, Orsolya
core   +1 more source